The business of editing genes to battle disease is bringing in record funding
When you’re sick, you can get treated with medicine or surgery. There’s a growing field, though, that looks at our own cells as treatment delivery systems. Many see it as the future of medicine, and that’s prompting a lot of investment in the field. This year, the industry is on track to raise more than $20 billion dollars, a record. That’s according to the Alliance for Regenerative Medicine, an advocacy group whose members include universities, foundations and major biopharma companies like Pfizer, Bayer and Johnson & Johnson. Marketplace’s Jed Kim talks to Janet Lambert, their CEO.